Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty
Asthmatx Inc. has announced that the Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee to the U.S. Food and Drug Administration (FDA) voted to recommend that the AlairĀ® System, a device utilized in bronchial thermoplasty for the treatment of severe persistent asthma in patients 18 years and older, be found approvable with conditions. The final decision regarding the approval of the device is made by the FDA.
- FDA states: Advisory labels too vague
- GenVec receives SBIR grant
- Study finds preventative effect of SLIT
- Hiberix vaccine receives accelerated approval
